Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | Mainland China | Atherosclerosis; Homozygous familial hypercholesterolemia | Amgen Inc | 2015-07-17 | Acute Coronary Syndrome; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Stroke; Homozygous familial hypercholesterolemia; Sepsis; Glioblastoma; Coronary Artery Disease; Hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Myocardial Infarction; Heart Failure; HIV Infections | Details |
| Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 波立达, Praluent | Mainland China | Dyslipidemias; Hypercholesterolemia; Atherosclerosis | Sanofi-Aventis Groupe | 2015-07-24 | Acute Coronary Syndrome; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Vascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hemorrhage; Stroke; Intracranial Arteriosclerosis; Homozygous familial hypercholesterolemia; Sepsis; Hypercholesterolemia; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Liver Diseases, Alcoholic; Plaque, Atherosclerotic; HIV Infections; Shock, Septic | Details |
| Inclisiran sodium | ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio | United States | Heterozygous familial hypercholesterolemia; Atherosclerosis | Novartis Pharma Ag | 2020-12-09 | Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Hypercholesterolemia; Kidney Diseases; Coronary Artery Disease; Acute Coronary Syndrome; Hypolipoproteinemias; Heterozygous familial hypercholesterolemia; Coronary Disease; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
| PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details | |
| SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
| NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
| Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Cardiovascular Diseases | Details | |
| Lodelcizumab | LGT-209; NVP-LGT-209 | Novartis Pharma Ag | Details | ||
| Recaticimab | SHR-1209 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| MEDI-4166 | MEDI-4166 | Medimmune Llc | Details | ||
| BMS-844421 | BMS-PCSK9; BMS 844421; BMSPCSK9Rx; ISIS-405879 | Ionis Pharmaceuticals Inc | Details | ||
| K-312 | K-312 | Kowa Co Ltd | Details | ||
| DC-371739 | DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias | Details |
| Ralpancizumab | RN 317; PF-5335810; PF-05335810 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| Ebronucimab | AK-102 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd, Yabao Us Pharmaceutical Co Ltd | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipidemia, Familial Combined | Details |
| MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
| Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined | Details |
| RBD-7022 | RBD-7022; RBD7022 | Phase 1 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypercholesterolemia; Dyslipidemias; Kidney Failure, Chronic; Hyperlipidemias | Details |
| AZD-0780 | AZD0780; AZD-0780 | Phase 1 Clinical | Astrazeneca Plc | Dyslipidemias | Details |
| Lerodalcibep | LIB-003 | Phase 3 Clinical | Lib Therapeutics Llc | Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
| MK-0616 | MK-0616 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Atherosclerosis; Hypercholesterolemia; Kidney Diseases; Hyperlipoproteinemia Type II | Details |
| NNC0385-0434 | NNC0385-0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Arteriosclerosis | Details |
| Ongericimab | JS-002 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Hypertriglyceridemia; Atherosclerosis; Hypercholesterolemia; Neoplasms; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
| ATH-04 | ATH-04 | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
This web search service is supported by Google Inc.
A-Z
